Improving cancer immunotherapy with DNA methyltransferase inhibitors.
Immunotherapy confers durable clinical benefit to melanoma, lung, and kidney cancer patients. Challengingly, most other solid tumors, including ovarian carcinoma, are not particularly responsive to immunotherapy, so combination with a complementary therapy may be beneficial. Recent findings suggest that epigenetic modifying drugs can prime antitumor immunity by increasing expression of tumor-associated antigens, chemokines, and activating ligands by cancer cells as well as cytokines by immune cells. This review, drawing from both preclinical and clinical data, describes some of the mechanisms of action that enable DNA methyltransferase inhibitors to facilitate the establishment of antitumor immunity.
['Saleh|Mohammad H|MH|', 'Wang|Lei|L|', 'Goldberg|Michael S|MS|']
D000818:Animals D019175:DNA Methylation D015254:DNA Modification Methylases D004791:Enzyme Inhibitors D006801:Humans D007167:Immunotherapy D009369:Neoplasms
Immunotherapy DNA methyltransferase inhibitor Epigenetic modifier CITIM 2015 Decitabine Ovarian cancer